Piper Jaffray analyst Christopher Raymond remains a buyer of Regeneron (REGN) shares after Phase 2 data from Roche's (RHHBY) VEGF/Ang2 bispecific RG7716 in diabetic macular edema. While RG7716 demonstrated stag-sig BCVA gains compared to Lucentis at week 24 in DME patients previously untreated with anti-VEGF therapies, key questions on safety and efficacy remain unanswered, he contends. Given this, the analyst thinks Regeneron's Eylea remains well-positioned in the DME space. Raymond reiterates an Overweight rating and $494 price target on Regeneron's shares.

Oppenheimer analyst Hartaj Singh raised the firm's price target on Regeneron to $1,175 from $1,125 and keeps an Outperform rating on the shares ahead of the Q1 earnings report on May 2. Oppenheimer believes the areas of focus will be the status and dynamics of the Eylea High Dose launch, questions around the impending Dupixent COPD PDUFA, the status of the two oncology approvals expected in 2024, updates on various pipeline projects in immunology and oncology, and comments on capital allocation and financial planning by the new CFO at the company.